Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.

Laboratory investigation; a journal of technical methods and pathology - 1 Apr 2007

Nakagomi Nami, Hirota Seiichi

Abstract excerpt

Aggressive systemic mastocytosis (ASM) is a very rare form of mast cell neoplasm that does not benefit from conventional chemotherapy. The majority of adult mast cell neoplasms and gastrointestinal stromal tumors (GISTs) have mutations in the proto-oncogene c-kit, which encodes the KIT receptor tyrosine kinase. The c-kit gene mutations are generally confined to the tyrosine kinase II domain in mast cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mastocytosis, Systemic

Share to Piperazines

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-kit

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 17259998
DOI: 10.1038/labinvest.3700524

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.PMID 17259998Read ↗

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibSemantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read ↗

Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His.Semantic proximity Read ↗

Molecular defects in mastocytosis: KIT and beyond KIT.Semantic proximity Read ↗

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.Semantic proximity Read ↗

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.Semantic proximity Read ↗

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.Semantic proximity Read ↗

Clustering of Activating Mutations in c-KIT’s Juxtamembrane Coding Region in Canine Mast Cell NeoplasmsSemantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.